Warfarin vs. Asprin in Reduced Ejection Fraction

More documents

Recommendations

Info

Financial Support Disclosures • National Institute of Neurological Disorders and Stroke U01-NS-043975 (S. Homma) U01-NS-039143 (J.L.P. Thompson) • No other disclosures • Warfarin, warfarin placebo provided by Taro Pharmaceuticals U.S.A. • Aspirin, aspirin placebo provided by Bayer HealthCare
Background • Heart failure patients are at an increased risk of death and stroke due to thromboembolic events • Warfarin and aspirin are often given to heart failure patients in sinus rhythm but they have not been compared to each other in a large group of heart failure patients
Page 1: WARFARIN vs. ASPIRIN in REDUCED CAR
Page 5 and 6: Key Inclusion Criteria 1. Normal si
Page 7 and 8: Statistical Design • Primary null
Page 9 and 10: Randomized, n Lost to Follow-up, n
Page 11 and 12: Baseline Medication Time in Therape
Page 13 and 14: Warfarin vs. Aspirin Hazard Ratios
Page 15 and 16: No. at risk Main Secondary Outcome
Page 17 and 18: Conclusions • No overall differen
Page 19 and 20: STUDY ORGANIZATION Sponsor - the Na

Warfarin vs. Asprin in Reduced Ejection Fraction

Create successful ePaper yourself

Delete template?

Save as template?